Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Antineoplastic Combined Chemotherapy Protocols"" wg kryterium: Temat


Tytuł:
Real-world first-line treatment of patients with BRAF -mutant metastatic colorectal cancer: the CAPSTAN CRC study.
Autorzy:
Martinelli E; Medical Oncology, Department of Precision Medicine, Università Degli Studi Della Campania Luigi Vanvitelli, Naples, Italy. Electronic address: .
Cremolini C; Oncologia Medica, University of Pisa, Pisa, Italy.
Mazard T; Institut de Recherche en Cancerologie de Montpellier, INSERM, Montpellier University, Institut du Cancer de Montpellier, Montpellier, France.
Vidal J; Department of Medical Oncology, Hospital del Mar - IMIM, CIBERONC, Barcelona, Spain.
Virchow I; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Tougeron D; Department of Hepato-gastroenterology, Poitiers University Hospital and University of Poitiers, Poitiers, France.
Cuyle PJ; Gastroenterology and Digestive Oncology Department, Imelda General Hospital, Bonheiden, Belgium.
Chibaudel B; Department of Medical Oncology, Hôpital Franco-Britannique - Fondation Cognacq-Jay, Levallois-Perret, France.
Kim S; Department of Medical Oncology, Centre Hospitalier Régional et Universitaire de Besançon, Besançon, France.
Ghanem I; Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain.
Asselain B; GINECO, Paris, France.
Castagné C; Pierre Fabre, Boulogne-Billancourt, France.
Zkik A; Pierre Fabre, Boulogne-Billancourt, France.
Khan S; Pierre Fabre, Boulogne-Billancourt, France.
Arnold D; Asklepios Tumorzentrum Hamburg AK Altona, Hamburg, Germany.
Pokaż więcej
Źródło:
ESMO open [ESMO Open] 2022 Dec; Vol. 7 (6), pp. 100603. Date of Electronic Publication: 2022 Nov 08.
Typ publikacji:
Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Colonic Neoplasms*/drug therapy
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/pathology
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Aged ; Female ; Humans ; Male ; Bevacizumab/therapeutic use ; Bevacizumab/adverse effects ; Irinotecan/pharmacology ; Irinotecan/therapeutic use ; Proto-Oncogene Proteins B-raf/genetics ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells.
Autorzy:
Wang X; School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City, China.
Xuetao X; School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City, China.; International Healthcare Innovation Institute (Jiangmen), Jiangmen City, Guangdong Province, China.
Wu M; School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City, China.
Wu P; School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City, China.; International Healthcare Innovation Institute (Jiangmen), Jiangmen City, Guangdong Province, China.
Sheng Z; School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City, China.; International Healthcare Innovation Institute (Jiangmen), Jiangmen City, Guangdong Province, China.
Liu W; School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City, China.; International Healthcare Innovation Institute (Jiangmen), Jiangmen City, Guangdong Province, China.
Ma YY; School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City, China.; International Healthcare Innovation Institute (Jiangmen), Jiangmen City, Guangdong Province, China.
Zhao DG; School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City, China.; International Healthcare Innovation Institute (Jiangmen), Jiangmen City, Guangdong Province, China.
Zhang K; School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City, China.; International Healthcare Innovation Institute (Jiangmen), Jiangmen City, Guangdong Province, China.
Li D; School of Biotechnology and Health Sciences, Wuyi University, Jiangmen City, China.; International Healthcare Innovation Institute (Jiangmen), Jiangmen City, Guangdong Province, China.
Zheng X; Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
Goodin S; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 542-553.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Docetaxel/*pharmacology
Prostatic Neoplasms/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/chemical synthesis ; Antineoplastic Combined Chemotherapy Protocols/chemistry ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Docetaxel/chemistry ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Esomeprazole/chemistry ; Esomeprazole/pharmacology ; Humans ; Male ; Molecular Structure ; NF-kappa B/antagonists & inhibitors ; NF-kappa B/metabolism ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/pathology ; Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Structure-Activity Relationship ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł:
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Autorzy:
Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale University and Yale Cancer Center, New Haven, Connecticut, USA.
Borate U; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.
Pollyea DA; Division of Hematology, Department of Medicine, University of Colorado, Aurora, Colorado, USA.
Brunner AM; Center for Leukemia, Massachusetts General Hospital, Boston, Massachusetts, USA.
Roncolato F; Department of Hematology, St George Hospital, Sydney, New South Wales, Australia.
Garcia JS; Department of Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Filshie R; Department of Hematology, St Vincent's Hospital, Melbourne, Victoria, Australia.
Odenike O; Section of Hematology/Oncology, University of Chicago Medicine and Comprehensive Cancer Center, Chicago, Illinois, USA.
Watson AM; Department of Hematology, Liverpool Hospital, Sydney, New South Wales, Australia.
Krishnadasan R; Department of Hematology, University of Arizona Cancer Center, Tucson, Arizona, USA.
Bajel A; Department of Clinical Hematology, Peter MacCallum Cancer Center and The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Naqvi K; Research and Development, Genentech Inc, South San Francisco, California, USA.
Zha J; Research and Development, AbbVie Inc, North Chicago, Illinois, USA.
Cheng WH; Research and Development, AbbVie Inc, North Chicago, Illinois, USA.
Zhou Y; Research and Development, AbbVie Inc, North Chicago, Illinois, USA.
Hoffman D; Research and Development, AbbVie Inc, North Chicago, Illinois, USA.
Harb JG; Research and Development, AbbVie Inc, North Chicago, Illinois, USA.
Potluri J; Research and Development, AbbVie Inc, North Chicago, Illinois, USA.
Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2023 Feb; Vol. 98 (2), pp. 272-281. Date of Electronic Publication: 2022 Nov 10.
Typ publikacji:
Multicenter Study; Clinical Trial, Phase I; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Myelodysplastic Syndromes*/drug therapy
Aged ; Humans ; Male ; Azacitidine/therapeutic use ; Leukemia, Myeloid, Acute/drug therapy ; Neutropenia/chemically induced ; Sulfonamides ; Treatment Outcome ; Female
Czasopismo naukowe
Tytuł:
Survival Outcomes of Epithelial Ovarian Cancer Patients Following Dose-dense Versus 3-Weekly Platinum-Paclitaxel Chemotherapy: A Meta-Analysis.
Autorzy:
Pergialiotis V; 1st Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: .
Liatsou E; 1st Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Thomakos N; 1st Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Liontos M; Department of Clinical Therapeutics, Division of Oncology, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Frountzas M; 1st Department of Propaedeutic Surgery, 'Hippocratio' General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Papapanagiotou A; 1st Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Rodolakis A; 1st Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Haidopoulos D; 1st Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Pokaż więcej
Źródło:
Clinical oncology (Royal College of Radiologists (Great Britain)) [Clin Oncol (R Coll Radiol)] 2023 Feb; Vol. 35 (2), pp. e189-e198. Date of Electronic Publication: 2022 Nov 07.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Carcinoma, Ovarian Epithelial*/drug therapy
Ovarian Neoplasms*/drug therapy
Female ; Humans ; Paclitaxel/therapeutic use ; Platinum/therapeutic use ; Proportional Hazards Models
Czasopismo naukowe
Tytuł:
Assessment of compliance with a color code protocol for non-elective cesarean section and its impact on time to delivery interval and neonatal outcomes.
Autorzy:
Vetier O; Department of Obstetrics, Gynecology, and Human reproduction, University Hospital of Rennes, France.
Yanni MA; Department of Obstetrics, Gynecology, and Human reproduction, University Hospital of Rennes, France.
Lassel L; Department of Obstetrics, Gynecology, and Human reproduction, University Hospital of Rennes, France.
Isly H; Department of Obstetrics, Gynecology, and Human reproduction, University Hospital of Rennes, France.
Beuchee A; Department of Pediatry, University Hospital of Rennes, France; University of Rennes, INSERM, LTSI - UMR 1099, Rennes F-35000, France.
Nyangoh-Timoh K; Department of Obstetrics, Gynecology, and Human reproduction, University Hospital of Rennes, France; University of Rennes, INSERM, LTSI - UMR 1099, Rennes F-35000, France.
Lavoue V; Department of Obstetrics, Gynecology, and Human reproduction, University Hospital of Rennes, France; University of Rennes, INSERM, LTSI - UMR 1099, Rennes F-35000, France.
Beranger R; Department of Obstetrics, Gynecology, and Human reproduction, University Hospital of Rennes, France; University of Rennes, INSERM, EHESP, Irset-UMR_S, Rennes 1085, France.
Le Lous M; Department of Obstetrics, Gynecology, and Human reproduction, University Hospital of Rennes, France; University of Rennes, INSERM, LTSI - UMR 1099, Rennes F-35000, France. Electronic address: .
Pokaż więcej
Źródło:
Journal of gynecology obstetrics and human reproduction [J Gynecol Obstet Hum Reprod] 2023 Feb; Vol. 52 (2), pp. 102520. Date of Electronic Publication: 2022 Dec 18.
Typ publikacji:
Journal Article
MeSH Terms:
Cesarean Section*
Antineoplastic Combined Chemotherapy Protocols*
Infant, Newborn ; Pregnancy ; Humans ; Female ; Retrospective Studies ; Hospitals, University
SCR Protocol:
PAVE protocol 2
Czasopismo naukowe
Tytuł:
Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma.
Autorzy:
Kim DW; Department of Mathematical Sciences, KAIST, Daejeon, South Korea.; Biomedical Mathematics Group, Institute for Basic Science, Daejeon, South Korea.
Byun JM; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea.
Lee JO; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Kim JK; Department of Mathematical Sciences, KAIST, Daejeon, South Korea.; Biomedical Mathematics Group, Institute for Basic Science, Daejeon, South Korea.
Koh Y; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea.
Pokaż więcej
Źródło:
JCI insight [JCI Insight] 2023 Jan 24; Vol. 8 (2). Date of Electronic Publication: 2023 Jan 24.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Lymphoma, Large B-Cell, Diffuse*/therapy
Adult ; Male ; Humans ; Female ; Rituximab/therapeutic use ; Antibodies, Monoclonal, Murine-Derived/adverse effects ; Treatment Outcome ; Vincristine ; Cyclophosphamide ; Prednisone ; Doxorubicin
Czasopismo naukowe
Tytuł:
Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study.
Autorzy:
Liu Y; Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Fan L; Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Wang ZH; Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Shao ZM; Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2023 Jan 18; Vol. 28 (1), pp. 86-e76.
Typ publikacji:
Clinical Trial, Phase II; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Neoadjuvant Therapy*/adverse effects
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/pathology
Female ; Humans ; Cyclophosphamide/therapeutic use ; Epirubicin/therapeutic use ; Paclitaxel/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Combined-modality treatment for locally advanced cervical cancer in a woman with Bloom-like syndrome: A case report and review of the literature.
Autorzy:
Ben Dhia S; Department of radiation therapy, Institut Curie, Paris, France. .
Berthou H; Department of radiation therapy, Institut Curie, Paris, France.
Warcoin M; Department of genetics, Institut Curie, Paris, France.
Rodrigues M; Department of surgery, Institut Curie, Paris, France.
Noret A; Department of medical oncology, Institut Curie, Paris, France.
Beddok A; Department of radiation therapy, Institut Curie, Paris, France.
Weber N; Department of anatomic pathology, Institut Curie, Paris, France.
Stoppa Lyonnet D; Department of genetics, Inserm U830, Institut Curie, Paris, France.; Paris University, Paris, France.
Scher N; Department of radiation therapy, Institut Curie, Paris, France.
Pokaż więcej
Źródło:
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] [Strahlenther Onkol] 2023 Jan; Vol. 199 (1), pp. 102-105. Date of Electronic Publication: 2022 Aug 05.
Typ publikacji:
Review; Case Reports; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Uterine Cervical Neoplasms*/radiotherapy
Female ; Humans ; Middle Aged ; Combined Modality Therapy ; Carboplatin/therapeutic use ; Paclitaxel/therapeutic use
Czasopismo naukowe
Tytuł:
A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer.
Autorzy:
Zhang Y; Department of Clinical Research, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China.
Wang ZX; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China.
Shen L; Department of Gastrointestinal Oncology, Beijing Cancer Hospital, Beijing, P. R. China.
Li J; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Shanghai, P. R. China.
Huang J; Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, P. R. China.
Su WG; HUTCHMED limited, Shanghai, P. R. China.
Zhang DS; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China.
Xu RH; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P. R. China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China.
Pokaż więcej
Źródło:
Cancer communications (London, England) [Cancer Commun (Lond)] 2023 Jan; Vol. 43 (1), pp. 150-153. Date of Electronic Publication: 2022 Nov 04.
Typ publikacji:
Letter
MeSH Terms:
Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/pathology
Antineoplastic Combined Chemotherapy Protocols*
Humans ; Benzofurans/therapeutic use ; Paclitaxel/therapeutic use ; Quinazolines/therapeutic use ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic
Opinia redakcyjna
Tytuł:
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).
Autorzy:
Sheng X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: doctor_.
Ye D; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhou A; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yao X; Department of Genitourinary Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Luo H; Department of Urologic Oncology, Chongqing University Cancer Hospital, Chongqing, China.
He Z; Department of Urology, Peking University First Hospital, Beijing, China.
Wang Z; Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhao Y; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ji Z; Urology Department, Peking Union Medical College Hospital, Beijing, China.
Zou Q; Department of Urology, Jiangsu Cancer Hospital, Nanjing, China.
He C; Department of Urology, Cancer Hospital of Henan Province, Zhengzhou, China.
Guo J; Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Tu X; Department of Urology, Jiangxi Province Tumor Hospital, Nanchang, China.
Liu Z; Department of Oncology, The First Hospital of Jilin University, Changchun, China.
Shi B; Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
Liu B; Department of Urology, The First Affiliated Hospital, School of Medical, Zhejiang University, Hangzhou, China.
Chen P; Department of Urology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China.
Wei Q; Department of Urology, West China Hospital Sichuan University, Chengdu, China.
Hu Z; Department of Urology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Zhang Y; Gastroenterology Department II, Harbin Medical University Cancer Hospital, Harbin, China.
Jiang K; Department of Gynecological and Genitourinary Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.
Zhou F; Urology, Cancer Center, Sun Yat-sen University, Guangzhou, China.
Wu D; Department of Urology, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China.
Fu C; Department of Urology, Liaoning Cancer Hospital & Institute, Shenyang, China.
Li X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wu B; Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China.
Wang L; Department of Oncology, Chinese PLA General Hospital, Beijing, China.
Qin S; Department of Oncology, Qinhuai Medical Area, Theater General Hospital of PLA, Nanjing, China.
Li G; Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Liu Y; Department of Oncology, The First Hospital of China Medical University, Shenyang, China.
Guo H; Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Chen K; Department of Medical Oncology II, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Zhang D; Department of Urology, Zhejiang Provincial People's Hospital, Hangzhou, China.
Wang G; Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Ding L; Betta Pharmaceuticals Co., Ltd., Hangzhou, China.
Wang Y; Betta Pharmaceuticals Co., Ltd., Hangzhou, China.
Yuan X; Betta Pharmaceuticals Co., Ltd., Hangzhou, China.
Guo J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: .
Pokaż więcej
Źródło:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Jan; Vol. 178, pp. 205-215. Date of Electronic Publication: 2022 Nov 01.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article
MeSH Terms:
Carcinoma, Renal Cell*/drug therapy
Kidney Neoplasms*/drug therapy
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Humans ; Everolimus/therapeutic use ; Protein Kinase Inhibitors/therapeutic use ; Receptors, Vascular Endothelial Growth Factor ; Vascular Endothelial Growth Factor A
Czasopismo naukowe
Tytuł:
Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy.
Autorzy:
Lee M; Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Kang JS; Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Kim H; Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Kwon W; Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Lee SH; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Ryu JK; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Kim YT; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Oh DY; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Chie EK; Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea.
Jang JY; Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
Journal of hepato-biliary-pancreatic sciences [J Hepatobiliary Pancreat Sci] 2023 Jan; Vol. 30 (1), pp. 111-121. Date of Electronic Publication: 2021 Oct 06.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Pancreatic Neoplasms*/diagnostic imaging
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/surgery
Humans ; Fluorouracil/therapeutic use ; Irinotecan/therapeutic use ; Leucovorin/therapeutic use ; Neoadjuvant Therapy
Czasopismo naukowe
Tytuł:
Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: A meta-analysis.
Autorzy:
Hu Y; Guilin Medical University, Guilin, China.
Zhou Z; Guilin Medical University, Guilin, China.
Luo M; Affiliated Hospital of Guilin Medical University, Guilin, China.
Pokaż więcej
Źródło:
Medicine [Medicine (Baltimore)] 2022 Dec 30; Vol. 101 (52), pp. e32207.
Typ publikacji:
Meta-Analysis; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Carcinoma, Non-Small-Cell Lung*/complications
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/complications
Lung Neoplasms*/drug therapy
Pleural Effusion, Malignant*/complications
Pleural Effusion, Malignant*/drug therapy
Humans ; Angiogenesis Inhibitors/therapeutic use ; Cisplatin/therapeutic use ; Endostatins/therapeutic use ; Quality of Life ; Randomized Controlled Trials as Topic ; Thrombocytopenia/epidemiology
Czasopismo naukowe
Tytuł:
Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells.
Autorzy:
Choupani E; Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Madjd Z; Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.; Oncopathology Research Center, Iran University of Medical Sciences, (IUMS), Tehran, Iran.
Saraygord-Afshari N; Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Kiani J; Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Hosseini A; Department of Medical Biotechnology, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Dec 22; Vol. 17 (12), pp. e0279522. Date of Electronic Publication: 2022 Dec 22 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Androgen Receptor Antagonists*/therapeutic use
Cyclin-Dependent Kinase 4*/antagonists & inhibitors
Triple Negative Breast Neoplasms*/drug therapy
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Cyclin-Dependent Kinase 6*/antagonists & inhibitors
Protein Kinase Inhibitors*/therapeutic use
Humans ; Cell Line, Tumor ; Receptors, Androgen/metabolism
Czasopismo naukowe
Tytuł:
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis.
Autorzy:
Kwag D; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Cho BS; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. .; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. .
Bang SY; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Lee JH; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Min GJ; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Park SS; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Park S; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Yoon JH; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Lee SE; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Eom KS; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Kim YJ; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Lee S; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Min CK; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Cho SG; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Lee JW; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Kim HJ; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2022 Dec 19; Vol. 12 (12), pp. 169. Date of Electronic Publication: 2022 Dec 19.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Leukemia, Myeloid, Acute*
Humans ; Aged ; Decitabine/therapeutic use ; Propensity Score ; Treatment Outcome ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Azacitidine/therapeutic use
Czasopismo naukowe
Tytuł:
Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis.
Autorzy:
Fiorica F; Department of Radiation Oncology and Nuclear Medicine, AULSS 9 Scaligera, 37045 Verona, Italy.
Buttigliero C; Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10093 Torino, Italy.
Grigolato D; Department of Radiation Oncology and Nuclear Medicine, AULSS 9 Scaligera, 37045 Verona, Italy.
Muraro M; Department of Radiation Oncology and Nuclear Medicine, AULSS 9 Scaligera, 37045 Verona, Italy.
Turco F; Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10093 Torino, Italy.
Munoz F; Radiation Oncology TomoTherapy Center, Hospital of Aosta, 11000 Aosta, Italy.
Tucci M; Department of Medical Oncology, Cardinal Massaia Hospital, 14100 Asti, Italy.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Dec 04; Vol. 29 (12), pp. 9511-9524. Date of Electronic Publication: 2022 Dec 04.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Docetaxel*/therapeutic use
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/pathology
Androgen Receptor Antagonists*/therapeutic use
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Humans ; Male ; Androgens/metabolism
Czasopismo naukowe
Tytuł:
The clinical characteristics and prognostic factors of 410 patients with natural killer/T-cell lymphoma.
Autorzy:
Sun Z; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
Wan W; Department of Oncology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhang X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
Zhang L; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
Li X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
Li L; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
Wang X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
Nan F; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
Yu H; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
Chang Y; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
Yan J; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
Li Z; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
Cui F; National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Ge J; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
XiaXu YD; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
Xu X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
Fu X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. zymfxr_.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China. zymfxr_.
Zhang M; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. mingzhi_.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China. mingzhi_.
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2022 Dec; Vol. 148 (12), pp. 3449-3459. Date of Electronic Publication: 2022 Jul 20.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Lymphoma, Extranodal NK-T-Cell*/drug therapy
Humans ; Prognosis ; Retrospective Studies ; Killer Cells, Natural/pathology ; DNA
Czasopismo naukowe
Tytuł:
Impact of relative dose intensity of R-CCOP regimen in elderly patients with diffuse large B-cell lymphoma in China.
Autorzy:
Gao H; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China.
Liu Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China.
Xu Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China.
Mi L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China.
Zhang C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China.
Wang X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China.
Song Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China.
Zhu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China. Electronic address: .
Liu W; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China. Electronic address: .
Pokaż więcej
Źródło:
Journal of the Formosan Medical Association = Taiwan yi zhi [J Formos Med Assoc] 2022 Dec; Vol. 121 (12), pp. 2556-2565. Date of Electronic Publication: 2022 Jul 01.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Aged ; Humans ; Retrospective Studies ; Rituximab/therapeutic use ; Cyclophosphamide/therapeutic use ; China ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.
Autorzy:
Calvo E; START Madrid - HM CIOCC, Hospital Madrid Norte Sanchinarro, Madrid, Spain.
Sessa C; Oncology Institute of Southern Switzerland, EOC, Ospedale San Giovanni, Bellinzona, Switzerland.
Harada G; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
de Miguel M; START Madrid - HM CIOCC, Hospital Madrid Norte Sanchinarro, Madrid, Spain.
Kahatt C; PharmaMar, Colmenar Viejo, Madrid, Spain.
Luepke-Estefan XE; PharmaMar, Colmenar Viejo, Madrid, Spain.
Siguero M; PharmaMar, Colmenar Viejo, Madrid, Spain.
Fernandez-Teruel C; PharmaMar, Colmenar Viejo, Madrid, Spain.
Cullell-Young M; PharmaMar, Colmenar Viejo, Madrid, Spain.
Stathis A; Oncology Institute of Southern Switzerland, EOC, Ospedale San Giovanni, Bellinzona, Switzerland.
Drilon A; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. .
Pokaż więcej
Źródło:
Investigational new drugs [Invest New Drugs] 2022 Dec; Vol. 40 (6), pp. 1263-1273. Date of Electronic Publication: 2022 Aug 10.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/pathology
Endometrial Neoplasms*/drug therapy
Endometrial Neoplasms*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/pathology
Female ; Humans ; Bevacizumab/therapeutic use ; Paclitaxel/therapeutic use
Czasopismo naukowe
Tytuł:
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.
Autorzy:
Campos S; Gynecologic Oncology Program, Dana-Farber Cancer Institute, 450 Brookline Ave, YC1420, Boston, MA, 02215, USA. Susana_.
Matulonis U; Gynecologic Oncology Program, Dana-Farber Cancer Institute, 450 Brookline Ave, YC1420, Boston, MA, 02215, USA.
Berlin S; Hematology Oncology, Lahey Health, 6 Tsienneto Rd Suite 101LL, Derry, NH, 03038, USA.
Horowitz N; Gynecologic Oncology Program, Dana-Farber Cancer Institute, 450 Brookline Ave, YC1420, Boston, MA, 02215, USA.
Liu J; Gynecologic Oncology Program, Dana-Farber Cancer Institute, 450 Brookline Ave, YC1420, Boston, MA, 02215, USA.
Krasner C; Gillette Center for Women's Cancers, Massachusetts General Hospital, 32 Fruit Street, Boston, MA, 02114, USA.
Hang L; Gillette Center for Women's Cancers, Massachusetts General Hospital, 32 Fruit Street, Boston, MA, 02114, USA.
Zarwan C; 41 Burlington Mail Road, Burlington, MA, 01805, USA.
Barry W; Gynecologic Oncology Program, Dana-Farber Cancer Institute, 450 Brookline Ave, YC1420, Boston, MA, 02215, USA.; Rho Federal Systems Division, Inc., 2635 E. NC Hwy 54, Durham, NC, 27713, USA.
Colella T; Gillette Center for Women's Cancers, Massachusetts General Hospital, 32 Fruit Street, Boston, MA, 02114, USA.
Whalen C; Gynecologic Oncology Program, Dana-Farber Cancer Institute, 450 Brookline Ave, DA117, Boston, MA, 02215, USA.
Shoni M; Obstetrics and Gynecology, Boston Medical Center, 88 Newton St. #2118, Boston, MA, 02118, USA.
Lundquist C; PACE Center-Clinical Research, Tufts Medical Center, 800 Washington St., Box 63, Boston, MA, 02111, USA.
Birrer MJ; Women's Cancer Clinic-Gynecology, University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, 449 Jack Stephens Drive, Little Rock, AR, 72205, USA.
Penson R; Gillette Center for Women's Cancers, Massachusetts General Hospital, 32 Fruit Street, Boston, MA, 02114, USA.
Pokaż więcej
Źródło:
International journal of clinical oncology [Int J Clin Oncol] 2022 Dec; Vol. 27 (12), pp. 1881-1890. Date of Electronic Publication: 2022 Nov 08.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/toxicity
Bevacizumab*/toxicity
Neoplasms*/drug therapy
Humans ; Carboplatin/therapeutic use ; Erlotinib Hydrochloride/therapeutic use ; Paclitaxel/therapeutic use
Czasopismo naukowe
Tytuł:
Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety.
Autorzy:
Shao YY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. Electronic address: .
Feng YH; Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Yen CJ; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Yang TS; Department of Hematology-Oncology, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.
Shen YC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Chao Y; Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
Chen JS; Department of Hematology-Oncology, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.
Su CY; Medical Division, Roche Products Ltd, Taipei, Taiwan.
Chen WJ; Medical Division, Roche Products Ltd, Taipei, Taiwan.
Hsiang HL; Medical Division, Roche Products Ltd, Taipei, Taiwan.
Hsu CH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Pokaż więcej
Źródło:
Journal of the Formosan Medical Association = Taiwan yi zhi [J Formos Med Assoc] 2022 Dec; Vol. 121 (12), pp. 2430-2437. Date of Electronic Publication: 2022 Sep 22.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/drug therapy
Humans ; Middle Aged ; Antibodies, Monoclonal, Humanized ; Bevacizumab
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz